Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
YJ001 Phase I MAD Study in DPNP
NCT06361108Phase 1Recruiting
- Sponsor
- Zhejiang Hanmai Pharmaceutical Technology Co., Ltd.
- Start
- May 2024
- Primary completion
- Dec 2025
- Modality
- Transdermal Patches, Hydrogel Systems, Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of YJ001 in diabetic polyneuropathy (DPN) (3 arms), sponsored by Zhejiang Hanmai Pharmaceutical Technology Co., Ltd. Primary endpoints: Safety Assessments - AEs, Safety Assessments - Number of Participants With Abnormal Laboratory Values and 1 more. Started May 2024; status: recruiting.
02
Drugs
YJ001
03
Conditions
diabetic polyneuropathy (DPN)
Beyond the preview
Go deeper on NCT06361108.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06361108.